Literature DB >> 15694996

Characterization of host immunity to cytomegalovirus pp150 (UL32).

Corinna La Rosa1, Zhongde Wang, Simon F Lacey, Susan F Markel, Madeva C Sharma, Joybelle Martinez, Maria M Lalimarmo, Don J Diamond.   

Abstract

The basic phosphoprotein 150 (pp150), the product of UL32 (unique long domain 32) gene of human cytomegalovirus (CMV), is an abundant component of the viral tegument and a target of human leukocyte antigen (HLA)-restricted cytotoxic T cells (CTLs) after infection. Identification of minimal cytotoxic epitopes (MCEs) from this CMV protein is of importance for peptide-based vaccines and immunotherapeutic approaches. Several pp150-specific CTL clones were derived from peripheral blood mononuclear cells of healthy CMV-positive donors with autologous fibroblasts infected either with CMV AD169 or with a recombinant vaccinia virus expressing full-length pp150 protein. HLA A*0301- and HLA A*6801-restricted CD8+ pp150 T-cell clones derived from different donors were found to efficiently kill autologous CMV-infected fibroblasts. Fine mapping of each MCE first used a T-cell epitope prediction algorithm. Overlapping peptides within the recognized regions were screened. The analysis identified pp150(792-802) and pp150(945-955) as MCEs for the HLA A*6801 and the HLA A*0301 pp150 clones, respectively. In vitro stimulation by recombinant modified vaccinia Ankara virus expressing full-length pp150 elicited high frequencies of CMV-CTL and interferon gamma production specific for the MCE identified in all subjects. The consistent presence of pp150 T cells in CMV-exposed individuals supports a role for this antigen in shaping the antiviral CTL response and indicates that pp150 could be a pivotal constituent of prophylactic and therapeutic CMV vaccines.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15694996     DOI: 10.1016/j.humimm.2004.10.008

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  8 in total

1.  Primary response against cytomegalovirus during antiviral prophylaxis with valganciclovir, in solid organ transplant recipients.

Authors:  Corinna La Rosa; Ajit P Limaye; Aparna Krishnan; Gideon Blumstein; Jeff Longmate; Don J Diamond
Journal:  Transpl Int       Date:  2011-06-14       Impact factor: 3.782

2.  DNA vaccine prime followed by boost with live attenuated virus significantly improves antigen-specific T cell responses against human cytomegalovirus.

Authors:  Anna Gil; Siyuan Shen; Scott Coley; Laura Gibson; Don J Diamond; Shixia Wang; Shan Lu
Journal:  Hum Vaccin Immunother       Date:  2013-07-25       Impact factor: 3.452

3.  Recombinant antibodies encoded by IGHV1-69 react with pUL32, a phosphoprotein of cytomegalovirus and B-cell superantigen.

Authors:  Christoph Steininger; George F Widhopf; Emanuela M Ghia; Christopher S Morello; Katrina Vanura; Rebecca Sanders; Deborah Spector; Don Guiney; Ulrich Jäger; Thomas J Kipps
Journal:  Blood       Date:  2012-01-10       Impact factor: 22.113

4.  A novel approach to evaluate the immunogenicity of viral antigens of clinical importance in HLA transgenic murine models.

Authors:  Aparna Krishnan; Zhongde Wang; Tumul Srivastava; Ravindra Rawal; Pooja Manchanda; Don J Diamond; Corinna La Rosa
Journal:  Immunol Lett       Date:  2008-08-13       Impact factor: 3.685

Review 5.  Neuropathogenesis of congenital cytomegalovirus infection: disease mechanisms and prospects for intervention.

Authors:  Maxim C-J Cheeran; James R Lokensgard; Mark R Schleiss
Journal:  Clin Microbiol Rev       Date:  2009-01       Impact factor: 26.132

6.  Microbial Cryptotopes are Prominent Targets of B-cell Immunity.

Authors:  Franz J J Rieder; Julia Biebl; Marie-Theres Kastner; Martina Schneider; Christof Jungbauer; Monika Redlberger-Fritz; William J Britt; Michael Kundi; Christoph Steininger
Journal:  Sci Rep       Date:  2016-08-19       Impact factor: 4.379

7.  Atomic structures and deletion mutant reveal different capsid-binding patterns and functional significance of tegument protein pp150 in murine and human cytomegaloviruses with implications for therapeutic development.

Authors:  Wei Liu; Xinghong Dai; Jonathan Jih; Karen Chan; Phong Trang; Xuekui Yu; Rilwan Balogun; Ye Mei; Fenyong Liu; Z Hong Zhou
Journal:  PLoS Pathog       Date:  2019-02-19       Impact factor: 6.823

8.  Chronic lymphocytic leukemia patients have a preserved cytomegalovirus-specific antibody response despite progressive hypogammaglobulinemia.

Authors:  Katrina Vanura; Franz Rieder; Marie-Theres Kastner; Julia Biebl; Michael Sandhofer; Trang Le; Robert Strassl; Elisabeth Puchhammer-Stöckl; Thomas Perkmann; Christoph F Steininger; Kostas Stamatopoulos; Wolfgang Graninger; Ulrich Jäger; Christoph Steininger
Journal:  PLoS One       Date:  2013-10-23       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.